-
1.发明授权Composition comprising material for inhibiting SCF or receptor thereof for treating or preventing diseases associated with vascular permeability 有权包含用于抑制SCF或其受体的材料用于治疗或预防与血管通透性相关的疾病的组合物公开(公告)号：US09528112B2
公开(公告)日：2016-12-27
申请号：US14398531
申请日：2012-10-25
Inventor： Won Hee Suh , Ji Yeon Kim
IPC: A61K38/18 , A61K38/17 , A61K31/713 , G01N33/68 , C12N15/115 , C07K16/28 , C07K16/24 , C12N15/113 , A61K39/00
CPC classification number: C12N15/115 , A61K31/713 , A61K38/17 , A61K38/18 , A61K2039/505 , C07K16/24 , C07K16/28 , C07K16/2803 , C07K2317/76 , C12N15/113 , C12N15/1136 , C12N15/1138 , C12N2310/11 , C12N2310/14 , C12N2310/16 , G01N33/6863 , G01N2333/52 , G01N2333/715 , G01N2500/02 , G01N2500/10 , G01N2800/7057
Abstract: The present invention relates to a composition comprising a material for inhibiting stem cell factor (SCF) or the receptor thereof for treating or preventing vascular permeability related diseases. Also, the present invention relates to a method for screening for an agent for treating vascular permeability related diseases, comprising the steps of: (a) treating a sample from a patient suspected of having a disease associated with vascular permeability with a candidate material; and (b) comparing the level of expression of the SCF or the receptor thereof with that of a control group. The present invention verifies SCF as a novel target for regulating vascular permeability. When the present invention is used, vascular permeability is decreased in diseases of the eye involving increased vascular permeability, thereby effectively treating or preventing vascular permeability related diseases. Also, vascular permeability can be effectively regulated using the composition. Further, the present invention can be provided as an effective means for screening an agent for treating vascular permeability related diseases by measuring the regulation of the expressions of SCF and c-Kit.
Abstract translation: 本发明涉及包含用于抑制干细胞因子（SCF）的材料或其受体用于治疗或预防血管通透性相关疾病的组合物的组合物。 此外，本发明涉及一种筛选用于治疗血管通透性相关疾病的药剂的方法，包括以下步骤：（a）用怀疑患有与血管通透性相关的疾病的患者用候选物质处理样品; 和（b）比较SCF或其受体的表达水平与对照组的表达水平。 本发明将SCF验证为调节血管通透性的新靶标。 当使用本发明时，涉及血管通透性增加的眼睛疾病中的血管通透性降低，从而有效地治疗或预防血管通透性相关疾病。 此外，可以使用组合物有效调节血管通透性。 此外，通过测量SCF和c-Kit的表达的调节，本发明可以作为筛选用于治疗血管通透性相关疾病的药剂的有效手段。
-
2.发明授权Composition for treating or preventing diseases caused by vascular permeability, containing imatinib or pharmaceutically acceptable salt thereof as active ingredient 有权用于治疗或预防由血管通透性引起的疾病的组合物，其含有伊马替尼或其药学上可接受的盐作为活性成分公开(公告)号：US09511068B2
公开(公告)日：2016-12-06
申请号：US14409441
申请日：2013-06-10
Inventor： Won Hee Suh , Ji Yeon Kim
IPC: A61K31/506 , C07D401/04
CPC classification number: A61K31/506 , C07D401/04
Abstract: The present invention relates to a pharmaceutical composition for treating or preventing diseases caused by vascular permeability, containing imatinib, which has been conventionally used as an agent for treating chronic myeloid leukemia, or a pharmaceutically acceptable salt thereof as an active ingredient, and a method for treating disease caused by vascular permeability using the composition. The pharmaceutical composition for treating or preventing diseases caused by vascular permeability of the present invention contains imatinib, which has been conventionally used as an agent for treating chronic myeloid leukemia, as an active ingredient, so as to provide a novel use of imatinib and to be able to effectively treat or prevent diseases caused by vascular permeability, and thus may be widely applied to develop a novel agent for treating diseases caused by vascular permeability.
Abstract translation: 本发明涉及用于治疗或预防由血管通透性引起的疾病的药物组合物，其含有伊马替尼，其通常用作治疗慢性骨髓性白血病的药物或其药学上可接受的盐作为活性成分， 使用该组合物治疗由血管通透性引起的疾病。 用于治疗或预防由本发明的血管渗透性引起的疾病的药物组合物含有作为常规用作治疗慢性骨髓性白血病的药物的伊马替尼作为活性成分，以提供伊马替尼的新用途，并且为 能够有效地治疗或预防由血管通透性引起的疾病，因此可广泛应用于开发用于治疗由血管渗透性引起的疾病的新型药剂。
-
3.发明申请Composition for Treating or Preventing Diseases Caused by Vascular Permeability, Containing Imatinib or Pharmaceutically Acceptable Salt Thereof as Active Ingredient 有权用于治疗或预防血管通透性引起的疾病的组合物，含有伊马替尼或其药学上可接受的盐作为活性成分公开(公告)号：US20150320750A1
公开(公告)日：2015-11-12
申请号：US14409441
申请日：2013-06-10
Inventor： Won Hee Suh , Ji Yeon Kim
IPC: A61K31/506
CPC classification number: A61K31/506 , C07D401/04
Abstract: The present invention relates to a pharmaceutical composition for treating or preventing diseases caused by vascular permeability, containing imatinib, which has been conventionally used as an agent for treating chronic myeloid leukemia, or a pharmaceutically acceptable salt thereof as an active ingredient, and a method for treating disease caused by vascular permeability using the composition. The pharmaceutical composition for treating or preventing diseases caused by vascular permeability of the present invention contains imatinib, which has been conventionally used as an agent for treating chronic myeloid leukemia, as an active ingredient, so as to provide a novel use of imatinib and to be able to effectively treat or prevent diseases caused by vascular permeability, and thus may be widely applied to develop a novel agent for treating diseases caused by vascular permeability.
Abstract translation: 本发明涉及用于治疗或预防由血管通透性引起的疾病的药物组合物，其含有伊马替尼，其通常用作治疗慢性骨髓性白血病的药物或其药学上可接受的盐作为活性成分， 使用该组合物治疗由血管通透性引起的疾病。 用于治疗或预防由本发明的血管渗透性引起的疾病的药物组合物含有作为常规用作治疗慢性骨髓性白血病的药物的伊马替尼作为活性成分，以提供伊马替尼的新用途，并且为 能够有效地治疗或预防由血管通透性引起的疾病，因此可广泛应用于开发用于治疗由血管渗透性引起的疾病的新型药剂。
-
4.发明申请COMPOSITION COMPRISING MATERIAL FOR INHIBITING SCF OR RECEPTOR THEREOF FOR TREATING OR PREVENTING DISEASES ASSOCIATED WITH VASCULAR PERMEABILITY 有权包含用于抑制SCF或受体的材料的组合物用于治疗或预防与血管渗透性相关的疾病公开(公告)号：US20150191729A1
公开(公告)日：2015-07-09
申请号：US14398531
申请日：2012-10-25
Inventor： Won Hee Suh , Ji Yeon Kim
IPC: C12N15/115 , C07K16/28 , G01N33/68 , C12N15/113
CPC classification number: C12N15/115 , A61K31/713 , A61K38/17 , A61K38/18 , A61K2039/505 , C07K16/24 , C07K16/28 , C07K16/2803 , C07K2317/76 , C12N15/113 , C12N15/1136 , C12N15/1138 , C12N2310/11 , C12N2310/14 , C12N2310/16 , G01N33/6863 , G01N2333/52 , G01N2333/715 , G01N2500/02 , G01N2500/10 , G01N2800/7057
Abstract: The present invention relates to a composition comprising a material for inhibiting stem cell factor (SCF) or the receptor thereof for treating or preventing vascular permeability related diseases. Also, the present invention relates to a method for screening for an agent for treating vascular permeability related diseases, comprising the steps of: (a) treating a sample from a patient suspected of having a disease associated with vascular permeability with a candidate material; and (b) comparing the level of expression of the SCF or the receptor thereof with that of a control group. The present invention verifies SCF as a novel target for regulating vascular permeability. When the present invention is used, vascular permeability is decreased in diseases of the eye involving increased vascular permeability, thereby effectively treating or preventing vascular permeability related diseases. Also, vascular permeability can be effectively regulated using the composition. Further, the present invention can be provided as an effective means for screening an agent for treating vascular permeability related diseases by measuring the regulation of the expressions of SCF and c-Kit.
Abstract translation: 本发明涉及包含用于抑制干细胞因子（SCF）的材料或其受体用于治疗或预防血管通透性相关疾病的组合物的组合物。 此外，本发明涉及一种筛选用于治疗血管通透性相关疾病的药剂的方法，包括以下步骤：（a）用怀疑患有与血管通透性相关的疾病的患者用候选物质处理样品; 和（b）比较SCF或其受体的表达水平与对照组的表达水平。 本发明将SCF验证为调节血管通透性的新靶标。 当使用本发明时，涉及血管通透性增加的眼睛疾病中的血管通透性降低，从而有效地治疗或预防血管通透性相关疾病。 此外，可以使用组合物有效调节血管通透性。 此外，通过测量SCF和c-Kit的表达的调节，本发明可以作为筛选用于治疗血管通透性相关疾病的药剂的有效手段。
-
-
-
Search Results
4
records
(took 0.021 seconds)
